In: BMC Infectious Diseases, 2015, vol. 15, p. 512
Extended-spectrum β-lactamases producing Escherichia coli (ESBL-E) are increasingly identified in health care facilities. As previously done for the control of methicillin-resistant Staphylococcus aureus, many hospitals have established screening strategies for early identification of patients being carriers of ESBL producers in general and ESBL-E in particular, and have implemented contact...
|
In: Enfermedades Infecciosas y Microbiología Clínica, 2014, vol. 32, no. 10, p. 623–624
|
In: Antimicrobial Agents and Chemotherapy, 2015, p. AAC.04450–14
Resistance to ß-lactams is constantly increasing, due to the emergence of totally new enzymes, but also to the evolution of pre-existing ß-lactamases. GES-1 is a clinically-relevant extended-spectrum β-lactamase (ESBL) hydrolyzing penicillins and broad-spectrum cephalosporins, but sparing monobactams and carbapenems. However, several GES-1 variants (i.e. GES-2 and GES-5) previously identified...
|
In: Journal of Medical Microbiology, 2014, vol. 63, no. Pt_5, p. 772–776
|
In: Antimicrobial Agents and Chemotherapy, 2014, p. AAC.02695–14
The whole sequence of plasmid pENVA carrying the extended-spectrum ß-lactamase gene blaCTX-M-15 was determined. It has been identified from a series of clonally-related Klebsiella pneumoniae ST274 strains recovered from companion animals. This plasmid was 253,984-bp in-size and harbored, in addition to blaCTX-M-15, a large array of genes encoding...
|
In: BioMed Research International, 2014, vol. 2014, p. e249856
The emergence of one of the most recently described carbapenemases, namely, the New Delhi metallo-lactamase (NDM-1), constitutes a critical and growingly important medical issue. This resistance trait compromises the efficacy of almost all lactams (except aztreonam), including the last resort carbapenems. Therapeutical options may remain limited mostly to colistin, tigecycline, and fosfomycin....
|
In: Antimicrobial Agents and Chemotherapy, 2014, vol. 58, no. 5, p. 2929–2933
Twenty-two consecutive carbapenem-resistant enterobacterial isolates were recovered from patients hospitalized between January and April 2013 in different units at a university hospital in Istanbul, Turkey. These were Klebsiella pneumoniae isolates producing the carbapenemases OXA-48, NDM-1, and KPC-2, Enterobacter cloacae isolates producing NDM-1, and Escherichia coli isolates producing OXA-48....
|
In: Antimicrobial Agents and Chemotherapy, 2014, vol. 58, no. 4, p. 2472–2474
Twelve consecutive carbapenem-resistant Escherichia coli isolates were recovered from patients (infection or colonization) hospitalized between March and September 2012 in different units at a hospital in Bulgaria. They all produced the carbapenemase NDM-1 and the extended-spectrum-β-lactamase CTX-M-15, together with the 16S rRNA methylase RmtB, conferring high-level resistance to all...
|
In: New Microbes and New Infections, 2014, vol. 2, no. 2, p. 50–51
We report here the first identification of the worldwide spread of Klebsiella pneumoniae carbapenemase-2-producing and carbapenem-resistant K. pneumoniae clone ST258 in Turkey, a country where the distantly-related carbapenemase OXA-48 is known to be endemic. Worryingly, this isolate was also resistant to colistin, now considered to be the last-resort antibiotic for carbapenem-resistant isolates.
|
In: Antimicrobial Agents and Chemotherapy, 2014, vol. 58, no. 2, p. 1269–1269
|
